Novo Nordisk's Wegovy linked to improved liver markers in MASH patients with BMI below 27

Bitget2026/11/08 18:52

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novo Nordisk reported improved liver markers with Wegovy 2.4 mg versus placebo in adults with MASH and liver scarring.
The post hoc phase 3 ESSENCE analysis covered 106 adults with BMI below 27 kg/m², showing improvements at 72 weeks.
Results showed reduced liver injury, disease activity and fibrosis markers; findings were presented at The Liver Meeting 2026 in Denver.
The exploratory findings supplement biopsy-based results in a population that may be overlooked because MASH is often associated with obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk's Wegovy linked to improved liver markers in MASH patients with BMI below 27

You may also like

Crypto prices